[1. Kobold S DP, Schnurr M, Subklewe M, RothenfusserS, Endres S. Immunotherapy in tumor-activated T-cells as a new treatment modality. Dtsch Arztebl Int. 2015;112:809-15.]Search in Google Scholar
[2. Makdisi G, Wang IW. Extra Corporeal Membrane Oxygenation (ECMO) review of a lifesaving technology. J Thorac Dis. 2015;7:E166-76.]Search in Google Scholar
[3. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.10.1056/NEJMoa1003466354929720525992]Search in Google Scholar
[4. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320-30.10.1056/NEJMoa141208225399552]Search in Google Scholar
[5. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006-17.10.1056/NEJMoa1414428574425825891304]Search in Google Scholar
[6. Squibb B-M. Opdivo (Nivolumab), Immune-Mediated Adverse Reactions Management Guide. (packet insert) 2015.]Search in Google Scholar
[7. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4:560-75.]Search in Google Scholar
[8. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH. Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med. 2015;373:288-90.10.1056/NEJMc1505197453995626176400]Search in Google Scholar
[9. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protectiveventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998;338:347-54.10.1056/NEJM1998020533806029449727]Search in Google Scholar
[10. Wohlfarth P, Ullrich R, Staudinger T, et al. Extracorporeal membrane oxygenation in adult patients with hematologic malignancies and severe acute respiratory failure. Critical care. 2014;18:R20.10.1186/cc13701405597624443905]Search in Google Scholar
